The Impact of Reported β-Lactam Allergy on Clinical Outcomes and Antibiotic Use Among Solid Organ Transplant Recipients

BACKGROUND: Reported β-lactam allergies (BLAs) are common and frequently inaccurate, but there are limited data on the clinical implications of BLA among solid organ transplant (SOT) recipients. We examined the impact of BLA on clinical outcomes and antibiotic use among SOT recipients. METHODS: This retrospective cohort study included adult patients undergoing single-organ heart, kidney, liver, lung, or pancreas transplant at a United States academic medical center from 1 April 2017 to 31 December 2020. Demographic and clinical data were collected from the electronic health record. Multivariate median regression was performed to evaluate the association between BLA and days alive and out of the hospital in the first 180 days posttransplant (DAOH180). Multivariate logistic regression was performed to evaluate the association between BLA and antibiotic use. RESULTS: Among 1700 SOT recipients, 285 (16.8%) had a BLA at the time of transplant. BLA was not associated with DAOH180 (adjusted median difference, –0.8 days [95% confidence interval {CI}, –2.7 to 1.2]; P = .43). Patients with BLA were more likely to receive intravenous vancomycin (adjusted odds ratio [aOR], 1.8 [95% CI, 1.3–2.6]; P < .001), clindamycin (aOR, 9.9 [95% CI, 5.1–18.9]; P < .001), aztreonam (aOR, 19.6 [95% CI, 5.9–64.4]; P < .001), fluoroquinolones (aOR, 3.8 [95% CI, 2.8–5.0]; P < .001), or aminoglycosides (aOR, 3.9 [95% CI, 2.5–6.2]; P < .001). CONCLUSIONS: BLA was associated with use of β-lactam alternative antibiotics but not DAOH180 among SOT recipients.